Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma
Lymphoma
About this trial
This is an interventional treatment trial for Lymphoma focused on measuring recurrent adult Hodgkin lymphoma
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically proven Hodgkin's lymphoma Progressive, relapsed, or refractory disease after prior chemotherapy, radiotherapy, and/or stem cell transplantation Epstein Barr virus (EBV) positive by immunohistochemical staining for LMP-1 or 2 OR the presence of EBV RNA (EBER) Availability of an HLA identical or haploidentical donor for cytotoxic T-lymphocytes, meeting the following criteria: EBV seropositive HIV negative HTLV-1 negative Hepatitis B surface antigen and hepatitis B core antibody IgM negative Hepatitis C antibody negative Must share at least 1 HLA haplotype with donor PATIENT CHARACTERISTICS: Age: 18 to 75 Performance status: Not specified Life expectancy: At least 8 weeks Hematopoietic: Not specified Hepatic: Bilirubin less than 2.0 mg/dL SGOT/SGPT less than 2.5 times normal (unless liver metastases are present) If there is liver involvement by disease, an obvious relationship between SGOT/SGPT and disease activity is required No hepatic dysfunction causing moribundity Renal: Creatinine clearance greater than 50 mL/min No renal dysfunction causing moribundity Cardiovascular: No cardiac dysfunction causing moribundity Pulmonary: No pulmonary dysfunction causing moribundity Other: No neurologic dysfunction causing moribundity No history of severe transfusion reactions with blood products (including fetal calf serum) Not pregnant PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: See Disease Characteristics No concurrent antimetabolites Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics Surgery: Not specified
Sites / Locations
- Penn State Cancer Institute at Milton S. Hershey Medical Center